Core Viewpoint - Sona Nanotech Inc. is advancing its Targeted Hyperthermia Therapy (THT) for cancer treatment, showcasing its research at the NCL's 20th anniversary symposium and providing updates on its operational activities and preclinical studies [2][3][4]. Company Updates - The Chief Scientific Officer of Sona Nanotech, Dr. Len Pagliaro, is presenting THT at the NCL symposium, highlighting the company's collaboration with leading organizations in nanomedicine [3]. - Sona has successfully closed an over-subscribed equity financing of $3.1 million in September, which will support its ongoing research and development efforts [5]. - Initial preclinical studies have confirmed that Sona's biocompatible gold nanorods (GNRs) are non-toxic and safe, leading to the commissioning of a full dose-escalation study to support a first-in-human early feasibility study planned for 2025 [5][7]. Research and Development - The company is conducting a preclinical study on THT for colorectal cancer at Dalhousie University, with results expected later in November [6]. - Sona's preclinical efficacy data indicates that THT can significantly reduce treated tumors and untreated metastases, prompting the company to pursue regulatory approvals for late-stage solid cancer treatments [7]. - The mechanism of action for THT involves using therapeutic heat delivered by infrared light absorbed by gold nanorods, which stimulates the immune system and enhances drug delivery to tumors [8]. Technology and Innovation - Sona Nanotech's gold nanorods are designed to be free of cetyltrimethylammonium (CTAB), mitigating toxicity risks associated with other gold nanorod technologies [9]. - The company is developing proprietary methods for manufacturing gold nanoparticles, which may be adapted for various medical applications pending regulatory approvals [9].
Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update